
ICON PLC
ICLRNASDAQTrading Snapshot
- Day Range
- $814.26 β $827.20
- 52-Week Range
- $66.57 β $203.91
- Volume
- $5.02B
- Avg Volume
- $4.09B
- Shares Outstanding
- 77.2M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $8.25B
- Last Q Revenue
- $2.06B
- P/E Ratio
- 183.4
- P/S Ratio
- 1.5x
- EPS (TTM)
- $0.90
- Dividend Yield
- β
Why Investors Own ICLR
- βHigh-growth profile β revenue up -9.5% YoY with expanding US Equity exposure.
- βHealthy economics β 70% gross margin and 20% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ICON PLC
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
ICON PLC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift ICLR price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
ICON PLC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.